Exosomes are having a moment. They’re trending on social media, major suppliers have launched new exosome ingredients at In-cosmetics Global 2026, and consumers are convinced they’re the next frontier in skincare.
Here’s the thing: the FDA hasn’t approved exosomes for cosmetic use (yet).
Read that again.
The cosmetic marketing machine is moving at breakneck speed. Science is moving slowly. That gap between what’s being promised and what’s actually been proven is the real story—and it’s dangerous.
What’s Happening - Right Now
Google searches for “exosomes” have risen 206% globally over the past 12 months. Exosome treatments in medispas and dermatologists’ offices are up 162%.
Recently, at In-Cosmetics Global 2026 (an annual industry trade show featuring major ingredient suppliers), DSM-Firmenich launched its cosmetic exosome ingredient, Exovive Lift, claiming a 30% boost in elasticity and the equivalent of 8 years of age reversal—both achieved after just two months.
Symrise, another major global ingredient supplier, introduced its own exosomes for deep skin regeneration.
These are major players, making very specific claims.
But here’s the head-scratcher: Cosmetic exosomes are a market that technically doesn’t exist yet, because nothing’s FDA-approved. Yet the category is already projected to hit $26.6 billion by 2035.
Wait, what? 😳
That’s not healthy industry momentum. That’s the cosmetics industry doing what it does best: marketing innovation faster than science can validate it.
Why These Claims Don’t Hold Up (Yet)
The “30% elasticity improvement” claim is based on two months of data. Credible skin elasticity claims typically require at least a 12+ week trial. And we don’t know whether those gains hold beyond two months or revert when you stop using the product, because DSM-Firmenich hasn’t disclosed that information.
The “equivalent to eight years of aging reduction” claim was also measured over the same two month in-house study. Claims of long term skin age reduction require studies of 6 months or longer.
There has been zero independent third-party validation, but DSM-Firmenich still claims this ingredient can boost skin elasticity 30% and reverse 8 years of skin aging in only eight weeks. 🤔
These claims feel vastly overstated without proper independant clinical scientific testing.
There’s also a regulatory gap: DSM-Firmenich is making serious claims of specific percentage improvements and years of age reversal, in a product category the FDA has not yet approved for cosmetic use. They’re saying “trust our in-house data” while regulators are still saying “we haven’t reviewed or cleared this yet.”
Even if DSM-Firmenich’s exosomes work, that doesn’t mean we understand how exosomes function in skincare broadly or what the long-term effects they have. One company’s internal study doesn’t validate a whole ingredient category that lacks independent clinical evidence and FDA approval.
I understand the market incentive - DSM-Firmenich just launched Exovive Lift, and there’s enormous pressure to make your mark within a new ingredient category before competitors enter and flood the space. If you want to secure your advantage, you have to make aggressive marketing claims, even if they aren’t properly validated.
Exosomes Have Already Hit The Market
Meet SickScience Labs.
They’ve built an entire skincare brand around proprietary exosome technology called NX35, and they’re selling it at Ulta Beauty, a mainstream retailer, without basic FDA oversight. They claim clinical validation from 8-week studies (there’s that 2-month thing again 🤨) involving 50 volunteers. Sounds solid, right? Except that those studies live only on their website. Not in peer-reviewed journals. Not anywhere you can actually dig into them, replicate them, or have someone independent verify them. And they’re marketing exosomes for topical skincare with zero FDA approval, zero long-term safety data, and zero established protocols.
So basically, they’ve built a brand around an evolving technology and decided to sell it before the FDA or any third-party scientific data validates its safety.
I say this as someone who deeply cares about consumer protection - SickScience isn’t nessesarily hiding anything. They’re just not being transparent. They call it “proprietary technology,” which is industry code for, “we’re not going to be clear about actual ingredients or percentages”, and , “we’re not letting anyone outside our company look at the data.”
If you’re thinking about buying an exosome product, understand you’re not just trying something new. You’re paying to become a test subject. There’s no oversight, no standard protocols - just a slick marketing story moving faster than science can validate its safety.
SickScience might have some solid in-house data, but they’re making a lot of specific claims based on those preliminary results. They’ve bet a whole brand on being first to market with a new ingredient category before regulators and independent scientists can catch up.
That’s a problem.
Facts Worth Knowing
No FDA approval. Zero. And the FDA has issued warning letters to companies making exosome claims. Despite this, products are flooding the market.
Exosomes are highly unstable. Without standardized manufacturing guidelines, the exosomes in one batch might not match the next. You could be buying a product with inconsistent or unstable active ingredients every time you repurchase.
The science behind exosomes is real, but it’s early. Exosomes have been proven to mediate cell-to-cell communication - that’s not hype. But an ingredient that shows “compelling scientific possibilities” and one that is “clinically proven for skincare” are two entirely different things. The claims lack rigorous, long-term testing for cosmetic applications.
The professional-versus-consumer divide is also quite blurry. In-office exosome treatments applied by trained practitioners are gatekept because they understand that the technology is still evolving. Consumer products are not. Regulatory clarity on the use of exosomes in topical skin treatments hasn’t been established.
How to Navigate This
If you’re a professional:
Don’t take the brand’s word for it. Ask for third-party clinical data—not just supplier studies.
Understand your liability here: if something goes sideways with an exosome treatment because the scientific data was questionable, you’re the one answering to the client complaint (or legal action), not the brand’s marketing department.
Your job is to be skeptical of non-validated technology on your client’s behalf. That skepticism is what protects you AND them.
If you’re a consumer look for these red flags:
Overtly dramatic before-and-afters (usually digitally manipulated).
Influencers who mysteriously forget to mention they’re being paid for their glowing review.
Claims about “cellular-level regeneration” with zero independant clinical evidence to back them up.
Ask where the exosomes come from—plant, human, lab-grown? The source should be clearly stated in the marketing copy.
See the term “proprietary formula”? Step away. That usually means the brand won’t be transparent about sources or percentages.
If the brand’s clinical studies exist only in-house and are not published in journals, that’s a warning sign. Important breakthroughs get published in scientific journals so that everyone can see them.
#MyTwoCents
Exosomes aren’t going anywhere. The science is promising, the market demand is real, and there’s genuine potential here. But right now, people are adopting this faster than we have answers. Some of what’s on the market will turn out to be overpromising. Some might actually deliver. We won’t know until there’s FDA approval for the category and actual clinical third-party scientific data to back it up.
What concerns me isn’t exosomes themselves. It’s the pace. We’re watching major suppliers launch ingredients with specific claims while the regulatory framework is still being written. The gap between what’s being promised and what’s been proven is dangerously wide.
Patience is a feature, not a limitation. This story will keep unfolding. Your skin can wait. The smart play? Stay curious, stay skeptical, and don’t let slick marketing stop your critical thinking.
Kevin James Bennett is the publisher of In My Kit®. He is an Emmy Award-winning makeup artist, cosmetic developer, educator, and consumer advocate.
Learn more at www.kjbennett.com